Davis Polk advised BBVA Banco Francés, S.A. in connection with its $ 400 million SEC - registered follow - on offering of 75,781,788 ordinary shares of Banco Francés, including ordinary
shares sold pursuant to exercise of the underwriters» over-allotment option.
HOUSTON, April 20, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000
shares sold pursuant to the underwriters» full exercise of their option to purchase additional shares, at a public offering price of $ 7.50 per share.
Not exact matches
Pursuant to our equity compensation plans and certain agreements with certain holders of our capital stock, including Jack Dorsey, Jim McKelvey, Khosla Ventures III, LP, entities affiliated with JPMC Strategic Investments, entities affiliated with Sequoia Capital, entities affiliated with Rizvi Traverse, and an entity affiliated with Mary Meeker, including an amended and restated right of first refusal and co-sale agreement, we or our assignees have a right to purchase
shares of our capital stock which stockholders propose to
sell to other parties.
If any covered officer is not in compliance with these stock ownership guidelines, he or she may not
sell or otherwise dispose of more than 50 percent of any
Shares that vest
pursuant to any equity award during any period for which he or she is not in compliance with such guidelines until such time as he or she is in compliance with the guidelines and such sale would not cause the covered officer to cease to be in compliance with the guidelines.
If any covered officer is not in compliance with the guidelines, he or she may not
sell or otherwise dispose of more than 50 percent of any Walmart
Shares that vest
pursuant to any equity award during any period for which he or she is not in compliance with the guidelines until such time as he or she is in compliance with the guidelines and such sale would not cause the covered officer to cease to be in compliance with the guidelines.
In December 2013, Shkreli determined that the Fearnow Escrow
Shares acquired by Fernandez and Tilles should be reallocated among Biestek, Fernandez and Tilles, and then sold to Shkreli pursuant to agreements that provided that Shkreli did not have to pay for the shares immediately, and could return them to Biestek, Fernandez and Tilles at his op
Shares acquired by Fernandez and Tilles should be reallocated among Biestek, Fernandez and Tilles, and then
sold to Shkreli
pursuant to agreements that provided that Shkreli did not have to pay for the
shares immediately, and could return them to Biestek, Fernandez and Tilles at his op
shares immediately, and could return them to Biestek, Fernandez and Tilles at his option.6
Other than the underwriting discount described on the front cover of this prospectus, the underwriters will not be entitled to any commission with respect to
shares of common stock
sold pursuant to the directed
share program.
the sale of
shares of common stock in an underwritten public offering that occurs during the restricted period, including any concurrent exercise (including a net exercise or cashless exercise) or settlement of outstanding equity awards granted under our equity incentive plans or
pursuant to a contractual employment arrangement described elsewhere in this prospectus in order to
sell the
shares of common stock delivered upon such exercise or settlement in such underwritten public offering; provided that, if required, any public report or filing under Section 16 of the Exchange Act will clearly indicate in the footnotes thereto that such disposition to us or withholding by us of
shares or securities was solely to us
pursuant to the circumstances described in this clause; or
Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the
shares may not be circulated or distributed, nor may the
shares be offered or
sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (1) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore, (2) to a relevant person, or any person
pursuant to Section 275 (1A), and in accordance with the conditions, specified in Section 275 of the Securities and Futures Act or (3) otherwise
pursuant to, and in accordance with the conditions of, any other applicable provision of the Securities and Futures Act.
Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the
shares may not be circulated or distributed, nor may the
shares be offered or
sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii) to a relevant person
pursuant to Section 275 (1), or any person
pursuant to Section 275 (1A), and in accordance with the conditions specified in Section 275 of the SFA or (iii) otherwise
pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to compliance with conditions set forth in the SFA.
All holders of Rule 701
shares, however, are required to wait until 90 days after the date of this prospectus before
selling those
shares pursuant to Rule 701.
Rule 701 generally allows a stockholder who purchased
shares of our Class A common stock
pursuant to a written compensatory plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding 90 days to
sell these
shares in reliance upon Rule 144, but without being required to comply with the public information, holding period, volume limitation or notice provisions of Rule 144.
We have based our calculation of the number of
shares outstanding after the offering and the percentage of beneficial ownership after the offering on
shares of our common stock outstanding immediately after the completion of this offering, including
shares that we estimate will be issued
pursuant to the 2014 Recapitalization assuming an initial public offering price of $ per
share (the midpoint of the price range on the cover of this prospectus), and no exercise of the underwriters» overallotment option to purchase
shares from the
selling stockholders.
Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the
shares may not be circulated or distributed, nor may the
shares be offered or
sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore (the «SFA»), (ii) to a relevant person
pursuant to Section 275 (1), or any person
pursuant to Section 275 (1A), and in accordance with the conditions specified in Section 275 of the SFA or (iii) otherwise
pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to compliance with conditions set forth in the SFA.
The
shares were issued in a transaction that was exempt from the registration requirements of the Securities Act of 1933, as amended (the «Securities Act»),
pursuant to Section 4 (a)(2) of the Securities Act and Regulation D promulgated thereunder inasmuch as the securities were offered and
sold solely to accredited investors and the Company did not engage in any form of general solicitation or general advertising in making the offering.
Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the
shares may not be circulated or distributed, nor may the
shares be offered or
sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore, or the «SFA,» (ii) to a relevant person, or any person
pursuant to Section 275 (1A), and in accordance with the conditions, specified in Section 275 of the SFA or (iii) otherwise
pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the ADSs or ordinary
shares may not be circulated or distributed, nor may the securities be offered or
sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor
pursuant to Section 274 of the Securities and Futures Act, Chapter 289 of Singapore, or SFA, (ii) to a relevant person (as defined in Section 275 (2) of the SFA), or any person
pursuant to Section 275 (1A), and in accordance with the conditions, specified in Section 275 of the SFA, or (iii) otherwise
pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
Rule 701 generally allows a stockholder who purchased
shares of our capital stock
pursuant to a written compensatory plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding 90 days to
sell these
shares in reliance upon Rule 144, but without being required to comply with the public information, holding period, volume limitation or notice provisions of Rule 144.
Accordingly, the Shareholder generally will recognize gain or loss on the sale in an amount equal to the difference between (1) the amount realized
pursuant to the sale of the
Shares, and (2) the Shareholder's tax basis for the portion of its pro rata
share of the Bitcoins held by the Trust at the time of sale that is attributable to the
Shares sold, as determined in the manner described in the preceding paragraph.
Until the
shares underlying the preferred stock and
shares underlying the warrants are registered, they may not be offered or
sold in the United States except
pursuant to an exemption from the registration requirements of the Securities Act and applicable state laws.
In the first step, VCA Antech will acquire a majority of the
shares of the company
pursuant to a stock purchase agreement entered into among VCA Antech, Pet DRx and certain
selling stockholders, which is expected to close within 30 days.
«The board of directors of the Company is pleased to announce that on 30th June 2014, the Company, Perfect Online Holding (the Company and Perfect Online collectively the Purchasers and each of them a Purchaser) and the shareholders (the Vendors) of Digital Extremes Ltd. entered into a non-binding term sheet,
pursuant to which the Purchasers intend to purchase, and Vendors intend to
sell, all the outstanding
shares of Digital Extremes, subject to due diligence and execution of definitive agreements between the parties.»
The Dyson Law Firm does not employ cookies,
sell or
share your information to third parties except
pursuant to a lawful order.
In addition to Smart, both the defendants Intel Corporation and School S.a.r.L.
sold Smart
shares pursuant to the IPO.
If you are submitting information to us
pursuant to a sweepstakes entry, we reserve the right to
share, loan, rent and / or
sell the information that you submit with and to our affiliates and other third parties.
Pursuant to such NYSE rules, and based upon information known to it at that time, Morgan Stanley is expected to provide input to the DMM regarding Morgan Stanley's understanding of the ownership of our outstanding ordinary
shares and pre-listing
selling and buying interest in our ordinary
shares that it becomes aware of from potential investors and holders of our ordinary
shares, in each case, without coordination with us.